New research was presented at SABCS 2017, the 40th annual San Antonio Breast Cancer Symposium, from December 5 to 9. The features here highlight some of the studies that emerged from the conference.
Cancer patients who initially chose alternative medicine (AM) rather than conventional therapies for treatment are more likely to die than others. Improved communication between patients and caregivers on the role of AM is warranted.
African Americans, Hispanics, and women appear less likely to be enrolled in cancer clinical trials than other groups of patients. Efforts are needed to increase recruitment that better represents the oncology patient population.
As immunotherapy moves to first-line cancer therapy, it is important to understand the long-term consequences of these agents and who is at higher risk of developing high-grade adverse events.
New research was presented at SABCS 2018, the annual San Antonio Breast Cancer Symposium, from December 4-8. The features included here highlight some of the studies that emerged from the conference.
This course discusses novel approaches to the use of neoadjuvant
chemotherapy in patients with breast cancer.
This course discusses the latest advances in neoadjuvant chemotherapy for the treatment of breast cancer.
This course discusses the key findings of five studies presented at the 2019 American Association for Cancer Research Annual Meeting.
This course discusses rates of patients with cancer and cancer survivors using complementary and alternative medicine (CAM) as well as rates of those not disclosing CAM use.